Tiziana Life Sciences Developing TZLS-501 as a Potential Treatment for Coronavirus Patients
Updated : 11:35
Tiziana Life Sciences Developing TZLS-501 as a Potential Treatment for Coronavirus Patients
PR Newswire
LONDON, March 11, 2020
LONDON, March 11, 2020 /PRNewswire/ -- Nasdaq and AIM listed Tiziana Life Sciences plc (Nasdaq: TLSA) (AIM: TILS) has today announced that its TZLS-501 treatment could be a potential treatment for patients infected with coronavirus (COVID-19) who are at risk of respiratory failure.
Tiziana, a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, is expediting development of TZLS-501, with Novimmune, SA, a Swiss biotechnology company with whom it entered into a world-wide license for composition-of-matter in 2017.
Tiziana plans to administer TZLS-501 using a proprietary formulation technology. Tests have already shown that the treatment rapidly depletes circulating levels of IL-6 in the blood. An excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with severe lung damage observed with COVID-19 infections and acute respiratory illness.
Dr. Kunwar Shailubhai, CEO & CSO of Tiziana Life Sciences said; "We are excited to move forward with our clinical development plan to expedite evaluation in patients as soon as possible."
For further enquiries:
Tiziana Life Sciences plc
Tiziano lazzaretti
+44 (0) 207-495-2379
Novus Communications
Alan Green/ John Brennan
+44 0207-448-9839
SOURCE Tiziana Life Sciences plc